Method of treating basaliomas

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for treating basaliomas. For this purpose dissection of affected skin portions is performed including healthy tissues within 0.5 cm by means of surgical laser with wavelength 810 nm pulse duration 0.2-0.5 seconds radiating power 15 W. After that 0.1% Radachlorin gel is applied on affected surface in terms 0.2 g per 1 cm2 of surface. 2-hour exposition under light-tight bandage. After gel removal surface is processed by laser light with wavelength 662 nm with light energy dose 200 J/cm2. Exposure is performed without contact. As laser radiation source, diode laser apparatus for photodynamic therapy "LAHTA-MILON" can be used.

EFFECT: method allows to prevent cosmetic defect, post-operation complications due to quick healing of affected area, stop of tumor growth of tissues, reduces method traumatism and number of recurrences.

2 cl, 2 ex

 

The invention relates to medicine, namely to laser medicine and can be used to treat basal cell carcinoma.

The known method of complex treatment of basal cell carcinoma of the skin, including acceptance of human leukocyte interferon in inhalations of 20 thousand UNITS a day, for a treatment course of 20 treatments, on the background of immune radio-removal of basal cell carcinoma on the device "Surgitron" (patent RU 2179000, 2002). The method has a qualitatively new approach and high efficiency in the treatment of basal cell carcinoma of the skin and correction of immunological parameters, leads to a high rate of recovery, characterized by the absence of relapses and complications of therapy.

There is a method of treating basal cell carcinoma, including the definition of the Central vnutriepetelialnaya zone of the lesion and the introduction to this area reaferona in the number of on-1500000-2000000 ED when the tumor size up to 2 cm2or quantity 2000000-3000000 ED when the tumor size > 2 cm2additionally impose Viferon rectal 500 UNITS and Viferon-gel to the lesion and the perimeter around it for 1-2 see Course 7-11 procedures (patent RU 2229306, 2004). The method allows to increase the effectiveness of treatment due to the absence of contraindications and complications such as bleeding, scarring, and recurrence.

The prototype of the invention is a method of treating basal cell carcinoma surgical nouvi the excision within healthy tissue (Snarskaya Y.S., Molochkov VA basal cell carcinoma. - M.: Medicine, 2003. - 136 C.). However, this method remains high frequency of recurrence of the disease, the emergence of a cosmetic defect in the form of postoperative scar, frequent complications in the form of joining a secondary infection.

The technical result - the cosmetic defect prevention, post-operative complications due to the rapid healing of the affected area, stop tumor growth of tissues, a reduction in the morbidity method and the number of relapses.

This technical result is achieved due to the fact that in the treatment of basal cell carcinoma, including excision of the tumor, according to the invention performed excision of the lesion with capture healthy tissue within 0.5 cm of the surgical laser with a wavelength of 810 nm, a pulse duration of 0.2-0.5 seconds, the radiation power of 15 W, after which the skin surface is applied 0.1%Radachlorin gel at the rate of 0.2 g per 1 cm2surface, exposure time 2 hours under light-tight bandage, and after removal of the gel treat the surface with a laser light wavelength of 662 nm at a dose of light energy of 200 j/cm2the impact carried out without contact. At the same time as the laser light source using a diode laser device for photodynamic therapy "LAHTA-MILON".

Offered the first method for the treatment of basal cell carcinoma is as follows: carry out excision of the lesion surgical laser with a wavelength of 810 nm, pulse duration of 0.2-0.5 seconds, the radiation power of 15 watts capture healthy tissue within 0.5 cm Then the entire skin surface impose photosensitizer 0.1%Radachlorin gel at the rate of 0.2 g per 1 cm2surface and cover with a light bandage. After 2 hours of exposure light-tight bandage is removed, sterile gauze cloth to remove remnants of Radachlorin gel and treat the entire surface with laser light wavelength of 662 nm at a dose of light energy of 200 j/cm2the impact carried out contactlessly using a fiber with a microlens. Dynamic monitoring is conducted after 1 week, 10 days, 1 month, 6 months and 12 months after treatment.

Authors in the available scientific and medical and patent literature not found information about the popularity of the proposed method of treatment of basal cell carcinoma using laser destruction in combination with photodynamic therapy. Thus, the claimed invention meets the criterion of "novelty".

The authors first established that the set of distinctive features of the process causes rapid healing of the affected area, halt tumor growth of tissues and a significant reduction in relapses, which allows us to get the specified technical result. Thus the m the claimed invention meets the criterion of "inventive step".

The proposed method is illustrated by the following examples.

Example 1. Patient Z. 43 years. Complaints when entering the presence of the ulcer on the skin of the bridge of the nose. Considers himself ill for about 3 years. Based on the data of anamnesis, clinical and cytological studies of a patient diagnosed with basal cell cancer, macronodular form, ulcerative type. The patient received excision education with capture of healthy tissue at a distance of 0.5 cm surgical laser with a wavelength of 810 nm, a pulse duration of 0.2-0.5 seconds, the radiation power of 15 watts. Then the entire skin surface caused photosensitizer 0.1%Radachlorin gel at the rate of 0.2 g per 1 cm2surface. After this, the affected area was covered with sterile light-tight bandage. After 2 hours of exposure light-tight bandage was removed and sterile gauze wipe excess was removed Radachlorin gel. Then the entire surface was processed with laser light with wavelength of 662 nm at a dose of light energy of 200 j/cm2the impact was carried out contactlessly using a fiber with a microlens. At the control examination after 1 week of treatment, the patient no complaints. The area of skin affected by the treatment, pokretanje-bloody crust, signs of inflammation there. Control examination after 10 days. The patient has no complaints. The crust on the skin has become thinner and smaller. Control examination after 1 month - no complaints, the crust was separated yourself on the 15th day after treatment. At the control examination after 6 months the patient has no complaints, the treated area is covered with delicate skin slightly pink. Control examination after 12 months after treatment - no complaints, the skin is clean, slightly whitish, with no signs of recurrence of the underlying disease and coarse cicatricial changes.

Example 2. Patient S. 51. Complaints on admission to the presence of small nodular growths with a rough surface on the skin of the right cheek. Objectively: on the surface of the skin of the right cheek has the education, oval in shape, with a diameter of 20 mm, with numerous branched, dark red telangiectasias and hemispherical pink-red papules with a diameter of 2-3 mm Considers himself sick about 4 years. Based on the data of anamnesis, clinical and cytological studies of a patient diagnosed with basal cell cancer, macronodular form, conglobata type.

The patient performed the excision education with capture healthy tissue 0.5 cm surgical laser with a wavelength of 810 nm, a pulse duration of 0.2-0.5 Sekou is d, the radiation power of 15 watts. Then the entire skin surface caused photosensitizer 0.1%Radachlorin gel at the rate of 0.2 g per 1 cm2surface. After this, the affected area was covered with sterile light-tight bandage. After 2 hours of exposure light-tight bandage was removed and sterile gauze cloth was removed excess Radachlorin gel. Then the entire surface was processed with laser light with wavelength of 662 nm at a dose of light energy of 200 j/cm2the treatment was carried out by the fiber with a microlens contactless. At the control examination after 1 week of treatment the patient no complaints. The area of skin exposed to treatment, is covered with serous-sanguineous crust, no detachable. Control examination after 10 days. The patient has no complaints. The crust on the skin significantly decreased in size, no signs of inflammation. Control examination after 1 month - no complaints, the crust was separated independently on day 12 after treatment, all treated surface without signs of inflammation and rough scarring. At the control examination after 6 months the patient has no complaints, the treated area is covered with delicate skin slightly pink. Control examination after 12 months after treatment - no complaints, the area affected by the treatment, virtually from ICUMSA from the surrounding skin, signs of recurrence of the tumor process no.

This method 167 patients treated with different types of basal cell carcinoma. In all cases, was achieved this technical result. The proposed method is easily reproducible in the hospital and clinics. Thus, the claimed invention meets the criterion of "industrial applicability".

1. A method of treating basal cell carcinoma, including excision of the tumor, characterized in that conduct excision of the lesion with capture healthy tissue within 0.5 cm of the surgical laser with a wavelength of 810 nm, a pulse duration of 0.2-0.5 s, the radiation power of 15 W, and then on the skin surface cause of 0.1% Radachlorin gel at the rate of 0.2 g per 1 cm2surface exposure 2 h under light-tight bandage, and after removal of the gel treat the surface with a laser light wavelength of 662 nm at a dose of light energy of 200 j/cm2the impact carried out without contact.

2. The method according to claim 1, wherein the source of laser radiation using a diode laser device for photodynamic therapy "LAHTA-MILON".



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: described are water-soluble mono-PEGylated derivatives of tetrapyrrole of formulas (1A) or (2), (values of radicals Y,B,R1,R4-R6 are given in invention formula), pharmaceutical composition, containing them, method of obtaining compound (2), including interaction of corresponding tetrapyrrole of general formula (7) with aminopolyethyleneglycol of formula H-Y, containing functionalised end fragment.

EFFECT: application of novel compounds as photosensibiliser in photodynamic therapy.

5 cl, 2 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula and their pharmaceutically acceptable salts and esters. The disclosed compounds have cdk4 inhibition properties. In formula (I) n equals 0 or 1; R1 and R2 are each independently selected from a group consisting of H, lower alkyl, CO2R5, SO2R6 and COR6; or alternatively, R1 and R2 can form a ring containing 5-6 atoms in the ring, where the said ring contains carbon atoms, where the said carbon atoms are optionally substituted with oxygen, and the said atoms in the ring are optionally substituted with OR6; R3 is selected from a group consisting of H, lower alkyl, O-lower alkyl, halogen, OH, CN, NO2 and COOH; R4 is selected from a group consisting of H, lower alkyl, C3-C6-cycloalkyl, O-lower alkyl, halogen, NO2, S-lower alkyl, NR5R6, CONR7R8, OH and CN; or alternatively R3 and R4, together with two carbon atoms and the bond between them from the benzene ring, to which R3 and R4 are bonded, can form a ring containing 5-7 atoms, where the said 5-7-member ring contains carbon atoms, where the said carbon atoms are optionally substituted with one or two heteroatoms selected from O and N, and the said atoms in the ring are optionally substituted with CO2R6; R4 represents H or halogen; R5 and R6 are each independently selected from a group consisting of H and lower alkyl; R7 and R8 each represents H. The invention also relates to a pharmaceutical composition for treating or controlling diseases progression of which can be enhanced by inhibiting cdk4, containing an effective amount of the disclosed compound as an active ingredient, to use of disclosed compounds for preparing medicinal agents and method of producing said compounds.

EFFECT: more effective treatment.

30 cl, 1 tbl, 142 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biologically active cation alkyl-type glycerolipid containing a fluorescent tag in its structure, and more specifically to Rac-N,N-dimethyl-N-[2-(5-N',N'-dimethylaminonaphthalene-1-sulfonyloxy)ethyl]-N-{4-[(2-methoxy-3-octadecyloxy)prop-1-yloxycarbonyl]butyl}ammonium iodide.

EFFECT: obtaining a novel compound which can be used in medicine as an anti-tumour agent.

1 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to composition for treating malignant disease, which contains ecteinascidin of general formula and disaccharide.

EFFECT: invention allows to provide compositions, which have high stability in storage, and essentially reduce formation of admixtures during liophylisation process and storage of ecteinascidin compositions.

36 cl, 5 ex, 19 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention relates to composition in form of solution, which contains17-AAG in amount up to 15 mg/ml, dissolved in carrier, which contains (i) first component, representing ethanol, in amount approximately from 40 to approximately 60 vol. %; (ii) second component, representing polyetoxylated castor oil, in amount approximately from 15 to approximately 50% vol. %; and (iii) third component, selected from group consisting of propylene glycol, "ПЭГ" 300, "ПЭГ" 400, glycerin and their combinations, in amount approximately from 20 to approximately 30 vol. %.

EFFECT: stable pharmaceutical composition in form of solution, which, when diluted with injection water, is suitable for intravenous introduction.

24 cl, 5 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: method involves reaction in aqueous medium of a diaquaplatinum or bis(nitrato)platinum complex in a mixture with dihalogenoplatinum with a block-copolymer of formula (1): or (2):, where R1 represents hydrogen or C1-C12-alkyl, L1 and L2 - connecting groups, R3 - hydrogen, a protective group for amino groups, a hydrophobic or polymerised group, R4 represents hydroxy-, carboxy- or a hydrophobic group, R5 represents hydrogen, an alkali metal ion or a protective group for the carboxylic group, m=5-20000, n=10-60, under the condition that, R5 - hydrogen or an alkali metal ion constitutes 50% or more in n links.

EFFECT: obtaining a conjugate which does not contain silver ions, the solution of which has lower particle-size distribution.

17 cl, 11 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: there is offered a monoclonal antibody specific to human interleukine-4 (hIL-4) containing two domains with the related CDR1-3 region. There are described versions thereof that contain specified CDR, polynucleotide coding said antibody. There are described an expression vector and a host-cell for preparing the antibody to human interleukine-4 (hIL-4). There are opened: application of the antibody for preparing a pharmaceutical agent for treating the diseases mediated by interleukine-4 and/or IgE. There is discovered the pharmaceutical composition for treating the diseases mediated by interleukine-4 and/or IgE is opened.

EFFECT: application of the invention ensured the high-affinity neutralised monoclonal antibodies to human interleukine-4.

14 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: crystalline monohydrate has X-ray powder pattern which includes four or more values 2θ, selected from a group consisting of: 18.0 ± 0.2, 18.4 ± 0.2, 19.2 ± 0.2, 19.6 ± 0.2, 21.2 ± 0.2, 24.5 ± 0.2, 25.9 ± 0.2 and 28.0 ± 0.2. The invention also relates to a method of producing crystalline monohydrate, to a pharmaceutical composition for treating disorders caused by protein tyrosine kinase containing crystalline monohydrate, to a crystalline butanol solvate of formula and to a crystalline ethanol solvate compound of formula (IV).

EFFECT: increased effectiveness of using said compounds.

8 cl, 1 tbl, 6 dwg, 12 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a drug for blood and immunity restoration in oncologic patients. The method for preparing the drug for blood and immunity restoration in oncologic patients involves infusion of mixed juice and pulp of clasping mullein (Verbascum phlomoides) and clasping long leaf (Verbascum longifolium) herbs on metal reduced iron powder under certain conditions, processing of the prepared suspension by a variable magnetic field followed with recovery of an end product. The drug for blood and immunity restoration in the oncologic patients is prepared by said method.

EFFECT: effectively restores blood and immunity in the oncologic patients.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to treatment of proliferative disease especially that one associated with a solid tumour. That is ensured by introduction of an effective amount of epothilone B of formula I wherein residual A represents O, R stands for hydrogen or methyl, and Z means O. The patient is exposed to ionising radiation additionally, simultaneously or consistently in any order.

EFFECT: choice of a specific epothilone derivative combined with radiation provides synergetic effect on suppression of tumour tissue.

8 cl, 1 ex

FIELD: medicine.

SUBSTANCE: method includes pulse transscleral impact of laser infra-red irradiation on ciliary muscle with application of visible radiation for fixation of look direction. Colour of radiation used for look direction fixation is changed, in such way control over condition of accommodative eye apparatus is exercised. Simultaneously power of pulse laser infra-red radiation influencing on ciliary muscle is changed. Other method version includes periodic dispersion of visible radiation, used for fixation of look direction, directly in front of eye pupil, ensuring impact of dispersed radiation on larger part of eye retina. Device includes unit for pulse transscleral impact of laser infra-red radiation on ciliary muscle of eye and look direction fixation, which includes generator of pulse laser infra-red radiation and generator of visible radiation. Device also contains control unit, connected with generator of visible radiation, made with possibility of changing colour and power of radiation, and with generator of pulse infra-red laser radiation for synchronisation of changing colour of visible radiation, changing of its power and changing power of laser radiation. Other version of device contains element with regulated dispersion of visible radiation, installed in exit pupil of generator. Generator of pulse infra-red laser radiation is made with possibility of synchronisation of changes in dispersion of visible radiation.

EFFECT: enhancing of effect of eye accommodation recovery.

14 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine, neurology. The method involves as follows. The points are exposed to the low intensity laser light generated with a light guide inserted through a needle. The exposure is performed at wave length 630 nm through the needle inserted at the angle 40 - 45° at the depth 30 - 35 mm. One of the points is a median located between spinous processes of vertebras adjoining the involved intervertebral disk. Three points are paravertebral and distanced 1.5 cm from each other and from spinous processes, while being aligned with a projection of intervertebral foramens. The exposure takes 5 minutes for each point. The therapy represents a course.

EFFECT: method activates reparative processes in tissues, reduces painful sensitivity due to reduced pulse activity of nervous fibres, while segmental-metameric bonds enable to create reflex phenomena of viscera.

3 cl, 2 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cosmetology and can be used as a method for therapeutic action on the patients with age-related skin changes. The method involves production of a biopsy preparation from gluteal region of the patient at least in 4 points of skin explant by punch-biopsy. The produced skin explant samples are used to grow a fibroblast culture. The patient is exposure to the after-biopsy intravascular laser autoblood irradiation course. It is followed with one to three transplantations of cultivated auto-fibroblasts at least every two weeks. Transplantation of fibroblasts is carried out at 5×109 cells per 1-2 cm2 of greater wrinkles or 5 cm2 of smaller wrinkles. The distance of intradermal injections within smaller wrinkles is 2-2.5 mm, while into greater wrinkles the cells are introduced by papule method. The laser irradiation course involves 10 daily procedures.

EFFECT: method provides higher effectiveness of correction of age-related skin changes including owing to improved blood supply, increased cell structure of derma and as consequence, improved skin elasticity and appearance.

2 ex, 2 dwg, 3 cl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, otorhinolaryngology, and can be used for laser treatment of chronic tonsillitis with using a photosensitiser. That is ensured by irrigation of tonsil lacunas with isotonic solution of sodium chloride with using a Hartmann cannula. A mixed photosensitiser solution and a pharmaceutically acceptable gel are prepared ex tempore. Herewith as a photosensitiser, water-soluble porphyrin of chlorine series is used. The prepared gel is introduced into tonsil lacunas. And amount thereof is 0.7 to 2 g for both tonsils and depends on size thereof, number and depths of lacunas. The gel is left in tonsils for 5-40 minutes. Tonsils are irrigated by lavage or above-stated technique with isotonic solution of sodium chloride to complete removal of residual photosensitiser. Then the tonsil surface is irradiated distantly at the end face of a light guide spaced 0.1-1.5 cm from tonsil surface. The irradiation is characterised with power density 80-400 J/cm2, radiation power 0.35-1.5 Wt and exposure 4-20 min for each tonsil.

EFFECT: method allows improving clinical effectiveness, reducing its cost and number and frequency of procedures, lowering collateral actions and treatment complications.

4 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, oncology, and can be used for treating spine osteochondrosis. That is ensured by percutaneous puncture approach to an invertebral disk. Then 2% sodium bicarbonate, 1% local anaesthetic and 70° alcohol are introduced in the invertebral disk consistently in equal portions. Then the patient is exposed to pulsed laser light emitted with a quartz light guide at wavelength 950-980 nm and at power 2-5 Wt. Laser exposition is 10-15 seconds, twice. Then laser exposure is continued with performing hernia evaporation of the invertebral disk.

EFFECT: method allows ensuring simultaneous elimination of irritation and compression syndromes in treatment of spine osteochondrosis of various locations.

3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medical equipment. Substance of the offered device consists that for irradiation of biological tissue, a fibre light guide is located within a sapphire capillary channel. Good optical transmission of sapphire in combination with its chemical inertness, high hardness, strength and thermal conductivity allows creating optically transparent irradiators-introducers with stabilisation of photothermal parametres of irradiation. Use of sapphire capillaries allows controlling distribution of laser light in tissue depending on the edge geometry and condition of internal and external capillary surfaces, improving regulation of light volume and extending the photodesctruction methods for treating the tumours.

EFFECT: small external diametre of capillaries, high p[purity of sapphire surface contacting the biological tissue provides their easy introduction and removal without accessory aids.

16 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and biology. The tumour area is irradiated with low intensity laser light of wave length 475 nm for 15 minutes per a session within the total course of 14 daily sessions.

EFFECT: method allows stimulating karyorhexis and karyopyknoss of tumour cell nuclei.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, to neurology. Method includes carrying out following procedures during one session: darsonval, laser therapy, vacuum therapy, acupuncture. Starting with the second day, additionally acupressure of compression zone with spasmolytics and chondroprotectors is performed. Staring with the third day, additionally therapeutic exercises are made. Treatment course includes from 8 to 15 procedures.

EFFECT: method reduces treatment terms and increases remission duration.

2 cl, 3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention concerns ophthalmology and aims at treating the patients suffering from deficiency in basal lachrymal secretion, i.e. with dry eye syndrome. Accessory lachrymal glands are stimulated with helium-neon laser light. That is transcutaneous pulse radiation of frequency 1 Hz, radiation pulse power 1.2 mWt and power flux density 0.513 mWt/cm2, daily exposition 2 minutes, 5-10 sessions in all. A projection of the whole area of each conjunctival fornix is irradiated alternately.

EFFECT: method ensures normalisation of microvascular blood flow, higher number of goblet cells, normalisation of size thereof, disappeared signs of conjunctival inflammation, improved functioning of tear-producing apparatus, rapid increase in tear production and prolonged effect.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine area, namely to otorhinolaryngology. Substance of the method consists in lasing of tonsillar bed following laser bilateral tonsillectomy of decompensated chronic tonsillitis by contact laser applications. Herewith mucous membrane is incised with indent 1-2 mm from front edge of anterior pillar from both sides distal part of end face of a light guide of a semiconductor laser "MILON-LAHTA" by continuous contact method at output laser power 8.5 Wt. Thereafter, through the incision, with using a raspatory, upper pole of palatine tonsil is separated with dislocating from tonsillar fossa. Laser radiation transmitted through a distal end face of the light guide by continuous contact method at laser power 9.5 Wt, adhesions and fusions between palatine tonsil and tonsillar fossa are gradually dissected to lower pole consequently cutting off from lateral wall. Bleeding sites of palatine tonsil bed are lased within 3 to 5 applications with distal end face of the light guide of the semi-conductor laser "MILON-LAHTA" by continuous contact method at laser power 8 Wt.

EFFECT: application of given invention allows for effective lasing of tonsillar bed following laser tosillectomy.

1 ex, 2 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine, otorhinolaryngology, and can be used for laser treatment of chronic tonsillitis with using a photosensitiser. That is ensured by irrigation of tonsil lacunas with isotonic solution of sodium chloride with using a Hartmann cannula. A mixed photosensitiser solution and a pharmaceutically acceptable gel are prepared ex tempore. Herewith as a photosensitiser, water-soluble porphyrin of chlorine series is used. The prepared gel is introduced into tonsil lacunas. And amount thereof is 0.7 to 2 g for both tonsils and depends on size thereof, number and depths of lacunas. The gel is left in tonsils for 5-40 minutes. Tonsils are irrigated by lavage or above-stated technique with isotonic solution of sodium chloride to complete removal of residual photosensitiser. Then the tonsil surface is irradiated distantly at the end face of a light guide spaced 0.1-1.5 cm from tonsil surface. The irradiation is characterised with power density 80-400 J/cm2, radiation power 0.35-1.5 Wt and exposure 4-20 min for each tonsil.

EFFECT: method allows improving clinical effectiveness, reducing its cost and number and frequency of procedures, lowering collateral actions and treatment complications.

4 cl, 1 tbl, 3 ex

Up!